Novel Rx Device for Sleep Apnea, Snoring Gets FDA Approval
The eXciteOSA device is used while the individual is awake and provides electrical muscle stimulation through a mouthpiece that sits around the tongue.
All articles by Steve Duffy
FDA Identifies Most Needed Meds to Address Urgent Medical Conditions
This action was in response to an executive order issued on August 6, 2020 aimed at protecting the public against outbreaks of emerging diseases and chemical, biological, radiological, and nuclear threats.
NIH: Study Will Identify Most Promising Therapies for COVID-19
So far, the therapies scheduled to be part of the trial are risankizumab, an interleukin-23 antagonist, and lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody.
US Cuts Deal With Pfizer, BioNTech for 100 Million COVID-19 Vaccine Doses
The US Department of Health and Human Services and the Department of Defense have agreed to receive 100 million doses of BNT162, a vaccine for SARS-CoV-2, once the manufacturers obtains approval or emergency use authorization (EUA) from the Food and Drug Administration.
Haymarket Medical Network Joins Ad Council Private Marketplace
Haymarket Medical Network, a part of business media company Haymarket Media, Inc., is proud to join the Ad Council’s first ever Private Marketplace (PMP) along with other partners Cadreon, The Trade Desk and Acxiom.
Taltz Approved for Pediatric Patients with Moderate to Severe Plaque Psoriasis
The FDA has approved the supplemental Biologics License Application (sBLA) for Taltz (ixekizumab: Lilly) injection for the treatment of pediatric patients aged ≥6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
FDA Approves OTC Combination of Ibuprofen and Acetaminophen
The FDA has approved Advil Dual Action with Acetaminophen, the first OTC fixed-dose combination therapy containing ibuprofen and acetaminophen for the temporary relief of minor aches and pains.
Comparative Efficacy of Systemic Psoriasis Treatments Evaluated
Among systemic treatments for plaque psoriasis, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were found to be associated with the highest Psoriasis Area and Severity Index (PASI) response rates.
Lower Dose Isotretinoin Formulation Available for Severe Recalcitrant Nodular Acne
If a second course of therapy is needed, it is not recommended before a 2-month waiting period because the patient’s acne may continue to improve following a 15 to 20-week course of therapy.
Novel Cell Therapy Gets Orphan Drug Status for Mucosal Pemphigus Vulgaris
Desmoglein 3 chimeric autoantibody receptor T cell therapy, is designed to selectively target the cause of mucosal pemphigus vulgaris.
-
Loading...
-
Loading...
Next post in General Dermatology
